Kura Oncology, Inc.

Healthcare · Biotechnology · United States

Last price 10.26 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 912.74M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n...